Artia Global Partners
Latest statistics and disclosures from Artia Global Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INSM, ARGX, SLNO, VRNA, QURE, and represent 54.71% of Artia Global Partners's stock portfolio.
- Added to shares of these 10 stocks: INSM (+$49M), QURE (+$39M), VRTX (+$20M), ABVX (+$19M), UGL (+$17M), SLNO (+$12M), TRVI (+$6.3M), ALNY (+$6.2M), RARE (+$5.2M), NAMS.
- Started 16 new stock positions in NKTR, KALV, DNTH, BBIO, RAPP, QURE, IREN, Sarepta Therapeutics, CNTA, OCUL. IONS, MRNA, BTSG, ALEC, ABVX, ATYR.
- Reduced shares in these 6 stocks: VRNA (-$68M), , SWTX, LLY, SRRK, JANX.
- Sold out of its positions in JANX, XBI, SWTX.
- Artia Global Partners was a net buyer of stock by $133M.
- Artia Global Partners has $631M in assets under management (AUM), dropping by 51.79%.
- Central Index Key (CIK): 0001937964
Tip: Access up to 7 years of quarterly data
Positions held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 48 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Insmed Com Par $.01 (INSM) | 25.8 | $163M | +42% | 1.1M | 144.01 |
|
| Argenx Se Sponsored Adr (ARGX) | 9.2 | $58M | 78k | 737.56 |
|
|
| Soleno Therapeutics (SLNO) | 7.2 | $45M | +35% | 672k | 67.60 |
|
| Verona Pharma Sponsored Ads (VRNA) | 6.4 | $40M | -62% | 379k | 106.71 |
|
| Uniqure Nv SHS (QURE) | 6.1 | $39M | NEW | 659k | 58.37 |
|
| Merus N V (MRUS) | 4.4 | $28M | 297k | 94.15 |
|
|
| Proshares Tr Ii Ultra Gold (UGL) | 3.9 | $25M | +219% | 537k | 46.06 |
|
| Eli Lilly & Co. (LLY) | 3.5 | $22M | -6% | 29k | 763.00 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.4 | $22M | +1152% | 55k | 391.64 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.0 | $19M | NEW | 226k | 84.90 |
|
| Trevi Therapeutics (TRVI) | 2.9 | $18M | +52% | 2.0M | 9.15 |
|
| Boston Scientific Corporation (BSX) | 2.8 | $18M | +18% | 183k | 97.63 |
|
| Alnylam Pharmaceuticals (ALNY) | 2.5 | $16M | +64% | 35k | 456.00 |
|
| Quest Diagnostics Incorporated (DGX) | 2.5 | $16M | 82k | 190.58 |
|
|
| Astrazeneca Sponsored Adr (AZN) | 2.3 | $15M | 191k | 76.72 |
|
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.4 | $8.9M | +98% | 628k | 14.24 |
|
| Ultragenyx Pharmaceutical (RARE) | 1.0 | $6.5M | +412% | 215k | 30.08 |
|
| Regeneron Pharmaceuticals (REGN) | 1.0 | $6.0M | 11k | 562.27 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.9 | $5.5M | +613% | 195k | 28.44 |
|
| Revolution Medicines (RVMD) | 0.8 | $4.9M | 104k | 46.70 |
|
|
| Avidity Biosciences Ord (RNA) | 0.8 | $4.8M | +218% | 110k | 43.57 |
|
| Dianthus Therapeutics (DNTH) | 0.7 | $4.3M | NEW | 109k | 39.35 |
|
| Ionis Pharmaceuticals (IONS) | 0.6 | $3.9M | NEW | 60k | 65.42 |
|
| Viking Therapeutics (VKTX) | 0.6 | $3.8M | +51% | 146k | 26.28 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.6 | $3.6M | -23% | 96k | 37.24 |
|
| Abbvie (ABBV) | 0.5 | $3.4M | 15k | 231.54 |
|
|
| Nektar Therapeutics Com New (NKTR) | 0.5 | $3.3M | NEW | 58k | 56.90 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.5 | $3.2M | NEW | 133k | 24.25 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.4 | $2.4M | 12k | 198.81 |
|
|
| Mineralys Therapeutics (MLYS) | 0.3 | $2.1M | +37% | 57k | 37.92 |
|
| United Therapeutics Corporation (UTHR) | 0.3 | $2.1M | 5.0k | 419.21 |
|
|
| Tg Therapeutics (TGTX) | 0.3 | $2.0M | 55k | 36.12 |
|
|
| Rapport Therapeutics (RAPP) | 0.3 | $1.9M | NEW | 65k | 29.70 |
|
| Ocular Therapeutix (OCUL) | 0.3 | $1.6M | NEW | 141k | 11.69 |
|
| Xenon Pharmaceuticals (XENE) | 0.3 | $1.6M | 40k | 40.15 |
|
|
| Iren Ordinary Shares (IREN) | 0.2 | $1.6M | NEW | 33k | 46.93 |
|
| Protagonist Therapeutics (PTGX) | 0.2 | $1.5M | 23k | 66.43 |
|
|
| Brightspring Health Svcs (BTSG) | 0.2 | $1.2M | NEW | 42k | 29.56 |
|
| Biohaven (BHVN) | 0.2 | $1.2M | 80k | 15.01 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.2 | $1.1M | 29k | 38.83 |
|
|
| Bridgebio Pharma (BBIO) | 0.2 | $1.1M | NEW | 20k | 51.94 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.2 | $979k | 475k | 2.06 |
|
|
| Sarepta Therapeutics | 0.1 | $865k | NEW | 45k | 19.27 |
|
| Travere Therapeutics (TVTX) | 0.1 | $739k | 31k | 23.90 |
|
|
| Atyr Pharma Com New (ATYR) | 0.1 | $701k | NEW | 972k | 0.72 |
|
| Moderna (MRNA) | 0.1 | $615k | NEW | 24k | 25.83 |
|
| Kalvista Pharmaceuticals (KALV) | 0.1 | $506k | NEW | 42k | 12.18 |
|
| Alector (ALEC) | 0.0 | $210k | NEW | 71k | 2.96 |
|
Past Filings by Artia Global Partners
SEC 13F filings are viewable for Artia Global Partners going back to 2022
- Artia Global Partners 2025 Q3 filed Nov. 14, 2025
- Artia Global Partners 2025 Q3 restated filed Nov. 14, 2025
- Artia Global Partners 2025 Q2 filed Aug. 14, 2025
- Artia Global Partners 2025 Q1 filed May 15, 2025
- Artia Global Partners 2024 Q4 filed Feb. 14, 2025
- Artia Global Partners 2024 Q3 filed Nov. 14, 2024
- Artia Global Partners 2024 Q2 filed Aug. 14, 2024
- Artia Global Partners 2024 Q1 filed May 15, 2024
- Artia Global Partners 2023 Q4 filed Feb. 14, 2024
- Artia Global Partners 2023 Q3 filed Nov. 14, 2023
- Artia Global Partners 2023 Q2 filed Aug. 14, 2023
- Artia Global Partners 2023 Q1 filed May 15, 2023
- Artia Global Partners 2022 Q4 filed Feb. 14, 2023